Cabazitaxel

A semi-synthetic taxane and microtubule inhibitor for the treatment of hormone-refractory prostate cancer; possesses a favorable pharmacokinetic and safety profile, and a decreased propensity for P-glycoprotein (Pgp) -mediated drug resistance.Chemotherapeutic Agents Approved (In Vitro) :The cytotoxicity of cabazitaxel (100 μg/mL) on 4T1 cells without irradiation is 70.8%. Cabazitaxel (100 μg/mL) exhibits a concentration-dependent antiproliferation effect, with the antiproliferative activity of 56.2%. (In Vivo) :Cabazitaxel (10 mg/kg, i.v.) has certain toxicity to liver and kidney but it can be avoided by integrated into Ans. The body weights of mice treated with AN-ICG-CBX and AN-CBX have a slightly decrease, while body weights of the free CBX group significantly decrease compared to the control group.